Document:

Exhibit 10.113

 

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH,
THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNLESS
AN EXEMPTION FROM REGISTRATION IS AVAILABLE UNDER THE SECURITIES ACT OF 1933 (THE "SECURITIES ACT").

 

CONVERTIBLE DEBENTURE

 

	$70,750.00	As of June 20, 2013

 

For value
received, VG Life Sciences, Inc. Formally known as Viral Genetics, Inc., a Delaware corporation (the "Company"),
promises to pay to the order of Dr. Eric Rosenburg (the "Holder"), the principal sum of SEVENTY THOUSAND AND SEVEN
HUNDRED AND FIFTY DOLLARS AND NO CENTS (the "Principal") and to pay interest on the outstanding Principal of this
Convertible Debenture (this "Debenture") as provided herein pursuant to the terms and provisions of this Debenture
as provided herein. This Debenture evidences various loans (each a "Loan") advanced by the Holder to the Company on
behalf of the Holder or on behalf of another entity pursuant to an agreement between the Holder and that entity, on the dates
and in the amounts specified on Schedule A attached hereto.

 

1.Definitions.

 

(a)"Business Day"
means any day on which banks are open for business in the State of California and the State of New York;

 

(b)"Common Stock"
means the Company's common stock, par value $0.0001 per Share.

 

(c)"Conversion
Price" shall be $0.20 per share; provided that the Conversion Price will be lowered to the lowest price per share that the Company issues Shares of Common Stock while this Debenture
is outstanding, but in no event less than $0.15 per Share.

 

(d)"Shares"
means shares of Common Stock;

 

(e)"Trading
Day" means a calendar day on which the Shares are quoted for trading on the Trading Market;

 

(f)"Trading
Market" means the following markets or exchanges on which the Shares are listed or quoted for trading on the date in
question: The Over The Counter Bulletin Board, the PinkSheets, the Nasdaq SmallCap Market, the American Stock Exchange, the
New York Stock Exchange, the Nasdaq National Market, the Toronto Stock Exchange, the TSX Venture Exchange,
or any other securities exchange registered with the United States Securities and Exchange Commission;

 

    	1

    	 

    

 

2.Interest.
Interest on the Principal amount of this Debenture will accrue at a rate equal to ZERO of a percent (0%) per annum from the date of the making of each Loan as set forth on Schedule A.
Interest will be computed on the basis of a 365-day year and will be paid on the Due Date.

 

3.Principal.
The Company shall pay the Principal amount of this Debenture, together with all accrued and unpaid interest, to Holder 07/1/2014 ("Due Date").

 

4.Payment.
All payments due under this Convertible Debenture shall be made in either the lawful money of the United States of America
or in Shares as determined according to this Section 4, without set-off, deduction, demand or notice.

 

(a)Form of Payment.
Ten (10) days prior to the Due Date, the Company, at its sole discretion, shall notify the Holder whether the payment due shall be made in cash or in Shares.

 

(b)Payments in
Cash. All payments in cash shall be made to the Holder by check or to such bank as the Holder may advise the Company in writing. The Company shall provide the Holder with
three (3) business days prior written notice of any cash payment of the amount outstanding under this Debenture.

 

(c)Payments in
Shares. The number of Shares issuable upon a payment being made in Shares or a conversion, as the case may be, shall be calculated
by dividing the outstanding Principal due on the Due Date or the date of a conversion, as the case may be, by the Conversion Price.
No fractional Shares will be issued upon conversion of this Debenture or a payment by the Company in Shares. In lieu of any fractional
Share to which the Holder would otherwise be entitled, the Company will pay to the Holder in cash the amount of the unpaid or
unconverted Principal and interest balance of this Debenture that would otherwise be paid or converted into such fractional Share.
Shares issued hereunder shall be transmitted by the transfer agent of the Company to the Holder either by crediting the account
of the Holder's designated broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission ("DWAC"),
or, if so elected by Holder, by physical delivery of certificates to Holder's address within five (5) Trading Days from the Due
Date. If the Company fails for any reason to deliver to the Holder the Shares by the requisite delivery date (whether a payment
by the Company or a conversion by the Holder), the Company shall pay to the Holder, in cash, as liquidated damages and not as
a penalty, for each $1,000 of Shares not timely delivered, $5 per Trading Day (increasing to $10 per Trading Day on the fifteenth
(15) Trading Day after such liquidated damages begin to accrue) for each Trading Day after such requisite delivery date until
such Shares are delivered. In addition to any other rights available to the Holder, if the Company fails to cause its transfer
agent to deliver to the Holder the Shares on or before the requisite delivery date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise), or the Holder's brokerage firm otherwise purchases, Shares
to deliver in satisfaction of a sale by the Holder of the Shares which the Holder anticipated receiving pursuant to this Debenture
(a "Buy-1n"), then the Company shall (1) pay in cash to the Holder the amount by which (x) the Holder's total purchase
price (including brokerage commissions, if any) for the Shares so purchased exceeds (y) the amount obtained by multiplying (A)
the number of Shares that the Company was required to deliver to the Holder multiplied by (B) the price at which the sell order
giving rise to such purchase obligation was executed, and (2) deliver to the Holder the number of Shares that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Shares having a total purchase price of $11,000 to cover a Buy-In with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (1) of the immediately preceding sentence the Company shall be required to pay the Holder $ 1,000. The
Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon
request of the Company, commercially reasonable evidence of the amount of the loss sustained by the Holder.

 

    	2

    	 

    

 

(d)Adjustments. If the Company, at any
time while this Debenture is outstanding subdivides outstanding Shares into a larger number of shares or combines (including by
way of reverse stock split) outstanding Shares into a smaller number of shares, then the Conversion Price shall be multiplied
by a fraction of which the numerator shall be the number of Shares outstanding immediately before such event and of which the
denominator shall be the number of Shares outstanding immediately after such event.

 

5.Prepayment.
Company shall have the right to prepay this Debenture in cash prior to the Due Date upon three (3) days prior written.

 

6.Conversion. All
or any portion of the Principal amount of this Debenture may be converted at the option of the Holder at any time and
from time to time, in the minimum principal amount of $25,000 and integral multiples of $5,000 thereafter, the Company's
receipt of the Conversion Notice (as hereinafter defined) from the Holder and payment in full of the Conversion Price as then
in effect. Each "Conversion Notice" shall mean a written notice from the Holder informing the Company of the date
of the conversion, the principal amount of this Debenture being converted, the number of shares of Common Stock to be
received upon conversion and confirming that the Conversion Price will be paid in cash. The Conversion Price shall be paid by
certified check or by wire transfer of immediately available funds to a bank account designated by the Company in writing.
Within three (3) Business Days after payment of the Conversion Price, the Company will deliver a certificate for the shares
of Common Stock issued upon conversion to the Holder, or at the Holder's request,
to a brokerage account for the benefit of Holder. The Company shall at all times reserve for issuance a number of shares of
Common Stock sufficient to satisfy the conversion feature of this Debenture. The number of shares of Common Stock
issuable upon the conversion of all or a portion of this Debenture shall be equal to the Principal amount of this Debenture
being converted divided by the Conversion Price. Upon conversion any accrued interest on the Principal amount of this
Debenture being converted shall be paid in cash or Shares, in the Company's discretion.

 

    	3

    	 

    

 

7.Default. Any one of the following occurrences
shall constitute an "Event of Default" under this Debenture:

 

(a)failure of
Company to pay any amount that it payable under this Debenture on the Due Date, provided that such failure is not cured within a grace period of ten (10) calendar days; or

 

(b)failure to
comply with or perform any other agreement or covenant of the Company contained herein, which failure does not otherwise constitute an Event of Default, provided that such failure
has not been cured within thirty (30) calendar days written notice by Holder to the Company; or

 

(c)there shall
occur any default or event of default, any similar event, any event that requires the prepayment of borrowed money or permits the acceleration of the maturity thereof, or any event
or condition that might become any of the foregoing with notice or the passage of time or both, under the terms of any evidence
of indebtedness or other agreement issued or assumed or entered into by the Company, or under the terms of any document or instrument
under which any such evidence of indebtedness or other agreement is issued, assumed, secured, or guaranteed, and such event shall
continue beyond any applicable notice, grace or cure period, provided that such condition shall not have been cured within thirty
(30) calendar days of notice by Holder; or

 

(d)the Company
shall fail to maintain its existence in good standing in its state of incorporation; provided that such condition shall not have been cured within thirty (30) calendar
days of notice by Holder; or

 

(e)a judgment
or settlement shall be entered or agreed to in any proceeding which would reasonably be expected to have a material and adverse effect on the ability of the Company to repay this
Debenture; or any garnishment, summons, writ of attachment, citation, levy or the like is issued against or served upon Holder
for the attachment of any property of the Company in Holder's possession or control, provided that such condition shall not have
been cured within thirty (30) calendar days of notice by Holder of such condition; or

 

(f)any
Share issued pursuant to this Debenture shall not be duly authorized, validly issued, fully paid or nonassessable, provided
that such condition shall not have been cured within ninety (90) calendar days
of notice by Holder of such condition; or

 

    	4

    	 

    

 

(g)the
Company shake make a voluntary filing for bankruptcy under Title 11, Chapter 7 of the United States Code; or

 

(h)there
shall be appointed a receiver or trustee to take possession of the property or assets of the Company under Title 11, Chapter 7
of the United States Code.

 

8.Remedies.
Upon the occurrence and during the continuance of an Event of Default, this Debenture shall become immediately due in full,
and unpaid amounts hereunder will accrue interest at the rate equal to the stated rate plus 5.00% per annum, and Holder may exercise
any rights and remedies under this Debenture, any Transaction Document or other document or instrument and at law or in equity.
The time of payment of this Debenture is also subject to acceleration if an Event of Default occurs. Notwithstanding the foregoing,
the entire unpaid Principal sum of this Debenture, together with accrued and unpaid interest thereon, shall become immediately
due and payable upon any of the Events of Default set forth in this Debenture.

 

9.Transfer;
Successors and Assigns. The terms and conditions of this Debenture shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. At the election of the Holder, but subject to compliance with applicable securities laws,
this Debenture may be assigned or transferred by the Holder, in whole or in part, upon surrender of this Debenture, duly endorsed,
and accompanied by a duly executed written instrument of transfer in customary form, following which a new Debenture for the same
principal amount and interest will be issued to, and registered in the name of, the transferee. If less than the entire amount
of this Debenture is transferred or assigned, the Company will issue new Debentures to the transferee, in the amount transferred
or assigned, and to the Holder, in the remaining Principal amount hereof after the transfer or assignment. This Debenture shall
be binding upon and inure to the benefit of the Company and the Holder, their successors and permitted assigns and the transferees
of the Holder.

 

10.Governing
Law. This Debenture and all acts and transactions pursuant
hereto and the rights and obligations of the Company and the Holder shall be governed, construed and interpreted in accordance
with the laws of the State of CALIFORNIA, without giving effect to any of its principles of conflicts of law or choice of
law principles which would result in the application of the laws of another jurisdiction.

 

11.Notices. Any
notice required or permitted by this Debenture shall be in writing and shall be deemed sufficient upon receipt, when
delivered personally or by courier, overnight delivery service or confirmed facsimile, or 96 hours after being deposited in
the U.S. mail as certified or registered mail with postage prepaid, if such
notice is addressed to the party to be notified at such party's address or facsimile number as set forth herein or as
subsequently modified by written notice.

 

    	5

    	 

    

 

12.Amendments
and Waivers. This Debenture may be amended by a written instrument executed by the Company and the Holder. Any amendment or
waiver effected in accordance with this Section 13 shall be binding upon the Company, the Holder and each transferee or permitted
assigns of any Debenture.

 

13.Loss of
Debenture. Upon receipt by the Company of a customary representation by the Holder of the loss, theft, destruction or mutilation of this Debenture or any Debenture exchanged for it,
and a customary indemnity undertaking by the Holder (in case of loss, theft or destruction) or surrender and cancellation of such
Debenture (in the case of mutilation), the Company will make and deliver in lieu of such Debenture a new Debenture of like tenor.

 

14.Waiver.
The Company hereby expressly waives presentment, demand for payment, dishonor, notice of dishonor, protest, notice of protest and any other formality upon the occurrence of an
Event of Default.

 

15.Costs and
Fees. The Company agrees to pay all costs, expenses, including, without limitation, reasonable attorneys' fees and disbursements, incurred by the Holder in endeavoring to collect any
amounts payable hereunder (including, without limitation, amounts payable in Shares) which are not paid when due or otherwise in
enforcing any provision of this Debenture and any of the rights and remedies of the Holder under this Debenture, at law or in equity.

 

[signature page follows]

 

    	6

    	 

    

 

This Debenture
has been executed as of the date first written above.

 

 

 

COMPANY

 

 

VG Life Sciences Inc.

 

By: signature illegible                           

Name:

Title:

 

 

 

 

 

 

 

    	7

    	 

    

 

Schedule A

 

 

 

 

 

 

 

 

 

 

 

 

    	8Exhibit 10.114

 

CONVERTIBLE PROMISSORY
NOTE

 AND WARRANT PURCHASE AGREEMENT

 

 

THIS CONVERTIBLE PROMISSORY
NOTE AND WARRANT PURCHASE AGREEMENT is made as of July 13, 2013, by and among MedBridge Venture Fund, LLC, a California limited
liability company (the “Investor”) and VG Life Sciences Inc. (the “Company” or “VGLS”).

 

THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1.Purchase and Sale of Notes.

 

1.1Purchase
and Sale of Note. Subject to the terms and conditions of this Agreement and pursuant to promissory notes in the form attached
hereto as Exhibit A (each a “Note” and, collectively, the “Notes”), the Investor agrees to purchase at the Closing
and the Company agrees to sell and issue to the Investor at the Closing and thereafter Notes in the principal amount of at least
Two Hundred Fifty Thousand Dollars ($250,000) and a maximum of Two Million Five Hundred Thousand Dollars ($2,500,000) at a price
equal to one hundred percent (100%) of the principal amount thereof (the “Investment”). Investor will pay a minimum
of $1, 440,000.00 in cash at the Closing, but shall be entitled to pay any amount above such amount in cash or the value of services
(“Services”) to be provided by Investor or its affiliates to the Company on or after the Closing, all as such Services
are described in Exhibit C hereto. A separate Note will be issued to Investor immediately following the lapse of each month during
which Investor or its affiliates have actually provided the Services to the Company, in the amounts contemplated in Exhibit C.
The Warrant (as defined in Section 1.2 below) includes a cashless exercise feature enabling conversion into unregistered shares
(“Shares”) of common stock of VGLS based on the spread between the warrant exercise price and the then-trading value
of the underlying VGLS Shares. The Note is convertible into Shares at a conversion rate equal to the lowest three-day average
closing price of the Shares starting on July 16, 2013 and ending on September 15, 2013 (the “Period”), minus a ten
percent (10%) discount. The Note will be convertible into Shares in four equal tranches (25% each) on the following dates: December
15, 2014, March 15, 2015, June 15, 2015, and September 15, 2015. With respect to the Note: (a) it carries an eight percent (8%)
per annum interest rate, (b) any unconverted principal and interest remaining on the Note on March 15, 2015 shall be automatically
converted into Shares on such date, and (c) it will not be prepayable by VGLS.

 

1.2Purchase and Sale of
Warrant. Subject to the terms and conditions of this Agreement, the Investor agrees to purchase and the Company agrees to sell
and issue to the Investor at the Closing, a warrant in the form attached hereto as Exhibit B (the”Warrant”) to purchase
shares of a series of the Company's Common Stock. In addition to the Notes, MVF will receive warrant coverage (“Warrants”)
for four Shares for every one dollar ($1.00) of cash or Services provided to the Company under Section 1.1. above, with each Warrant
to be exercisable by Investor at $0.45 per Share, which includes a cashless exercise feature. The Warrants will be exercisable
on any date from and including the four-year anniversary of the date of this Agreement and the five-year anniversary thereof.

    	1

    	 

    

1.3Closing.

 

(a)The purchase and sale
of the initial Note and Warrants shall take place at the offices of Investor at 10:00 A.M. between September 15, 2013 and November
30, 2013, or at such other time and place as the Company and the Investor may determine (the “Closing”).

 

(b)At the Closing, the Company
shall deliver to the Investor a Note representing the principal amount as is prescribed in Section 1.1 above and the Investor shall
cause to be delivered to the Company a wire transfer to the Company's order in the aggregate amount of the principal amount of
the Investment as is prescribed in Section 1.1 above.

 

(c)Following the Closing the
Company shall deliver additional Notes and Warrants as the cash or Services described in Section 1.1 above are provided to the
Company.

 

1.4Change of Control.
Notwithstanding anything to the contrary set forth in this Agreement, in the event of a “Change of Control” of VGLS,
Investor shall be entitled to receive (prior to the close of any such Change of Control) any remaining Notes for the full value
of the Services that MDC would have provided to VGLS hereunder during the full term of this Agreement absent such Change of Control,
and the Shares to which Investor would have been entitled to under the Notes or the conversion thereof absent such Change of Control.
In addition to the foregoing, in the event of a Change of Control of VGLS, Investor shall be entitled to receive and exercise (prior
to the close of any such Change of Control) any and all corresponding Warrants to which it would have been entitled under Sections
1.1 and 1.2 above during the full term of this Agreement absent such Change of Control, and the Shares exercisable under the Warrants.
For purposes of this Section 1.4 a “Change in Control” shall mean; (a) the closing of the sale, transfer or other disposition
of all or substantially all of the VGLS’s assets, (b) the consummation of the merger or consolidation of VGLS with or into
another entity (except a merger or consolidation in which the holders of capital stock of VGLS immediately prior to such merger
or consolidation continue to hold at least fifty percent (50%) of the voting power of the capital stock of VGLS or the surviving
or acquiring entity), or any transaction or series of transactions to which VGLS is a party in which in excess of fifty percent
(50%) of VGLS’s voting power is transferred, or (c) the exclusive license of all or substantially all of the intellectual
property of VGLS to a third party.

 

2.Representations, Warranties,
and Covenants of the Company. The Company hereby represents and warrants to the Investor that:

 

2.1Organization, Good Standing
and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the
State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and proposed to
be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure
to so qualify would have a material adverse effect on its business or properties.

    	2

    	 

    

2.2Authorization.
All corporate actions on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement, the performance of all obligations of the Company hereunder and the authorization, issuance and
delivery of the Notes and the Warrants have been taken or will be taken prior to the Closing. This Agreement constitutes, and the
Notes and the Warrants when executed and delivered in accordance with their terms will constitute, valid and legally binding obligations
of the Company, enforceable in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, and other laws of general application affecting enforcement of creditors' rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies and (iii)
as limited by applicable usury laws.

 

2.3Compliance with Other
Instruments. The Company is not in violation or default of any provisions of its Articles of Incorporation, as amended (the
“Articles”), or Bylaws (the “Bylaws”), or, except as set forth on Schedule 1 hereof, in any material respect
of any provision of a mortgage, indenture, agreement, instrument or contract to which it is a party or by which it is bound or
of any federal or state judgment order, writ or decree, or, to its knowledge, of any statute, rule or regulation applicable to
the Company. The execution, delivery and performance by the Company of this Agreement, and the consummation of the transactions
contemplated hereby, including the issuance and delivery of the Notes and the Warrants, will not result in any such violation or
be in material conflict with or constitute, with or without the passage of time or giving of notice, either a material default
under any such provision or an event that results in the creation of any material lien, charge or encumbrance upon any assets of
the Company or the suspension, revocation, impairment,forfeiture, or nonrenewal of any material permit, license, authorization,
or approval applicable to the Company, its business or operations, or any of its assets or properties.

 

2.4Governmental Consents.
Based in part upon the representations and warranties of the Investor in Section 3, no consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority
on the part of the, Company is required in connection with the consummation of the transactions contemplated by this Agreement,
except such post-closing filings as may be required under applicable federal and state securities laws, which will be timely filed
within the applicable period therefor.

 

2.5Sufficient Authorized
Shares. The number of authorized but unissued shares of the Company's Common Stock will be sufficient to permit conversion
of the Notes and the exercise of the Warrants. From the date hereof, the Company shall at all times maintain a sufficient quantity
of authorized but unissued shares of Common Stock sufficient to permit conversion of the Notes and the exercise of the Warrants.
In the event the Company, for any reason, no longer has a sufficient number of authorized but unissued shares to comply with this
Section 2.5, it shall use its best efforts to promptly authorize such shares. Upon the issuance of shares of Common Stock pursuant
to the conversion of the Notes and/or the exercise of the Warrants, such shares of Common Stock shall be duly and validly issued,
fully paid and nonassessable, and issued in compliance with all applicable securities laws, as then in effect, of the United States
and each of the states whose securities laws govern the issuance of the Notes and/or the Warrants pursuant to this Agreement and
shall not be issued in violation of any preemptive or similar right.

    	3

    	 

    

 

2.6No Brokers. No broker
or finder has acted directly or indirectly for the Company in connection with the transactions contemplated by this Agreement,
and no broker or finder is entitled to any brokerage, finder's or other fee or commission in respect thereof based in any way on
agreements, arrangements or understandings made by or on behalf of the Company and the Investor or the transactions contemplated
hereby.

 

2.7Minute Books. The
Company has made available to the Investor (and will continue to make available up to the Closing) copies of the minute books of
the Company. The minute books contains records of all written actions and meetings of the Board of Directors and there have been
no written actions or meetings of the Board of Directors since the date of the last meeting in the minute books.

 

3.Representations and
Warranties of the Investor. The Investor represents and warrants severally and not jointly, with respect to the Investor, that:

 

3.1Authorization. The
Investor has full capacity, power and authority to enter into and perform this Agreement, and all actions necessary to authorize
the execution, delivery and performance of this Agreement have been taken prior to the Closing. This Agreement constitutes a valid
and legally binding obligation of the Investor, enforceable in accordance with its terms, except as the same may be limited by
bankruptcy, insolvency, moratorium, and other laws of general application affecting the enforcement of creditors' rights generally.

 

3.2Receipt of Information.
The Investor believes it, he or she has received all the information necessary or appropriate for deciding whether to acquire the
Securities. The Investor further represents that the Investor has had an opportunity to ask questions and receive answers from
the Company regarding the terms and conditions of the offering of the Securities.

 

3.3Investment Experience.
The Investor is an investor in securities of companies in the development stage and acknowledges that the Investor is able to fend
for itself, herself or himself, can bear the economic risk of its, his or her investment and has such knowledge and experience
in financial or business matters that the Investor is capable of evaluating the merits and risks of the investment in the Securities.
If other than an individual, the Investor also represents it has not been organized for the purpose of acquiring the Securities.
The Investor further represents that the information provided on Investor's counterpart signature page is true and accurate.

 

3.4Restricted
Securities. The Investor understands that the Securities are characterized as "restricted securities" under the
federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering
and that under such laws and applicable regulations such securities may be resold without registration under the Securities
Act of 1933, as amended (the "Securities Act") only in certain limited circumstances. In connection therewith, each
lender represents that it is familiar with Rule 144 under the Securities Act, as presently in effect, and understands the
resale limitations imposed thereby and by the Securities Act.

    	4

    	 

    

 

3.5Legends. To the extent
applicable, each certificate or other document evidencing any of the Securities shall be endorsed with the legend set forth below,
and the Investor covenants that, except to the extent such restrictions are waived by the Company, the Investor shall not transfer
the Securities represented by any such certificate without complying with the restrictions on transfer described in the legends
endorsed on such certificate:

 

"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED ABSENT
AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SUCH ACT, OR UNLESS THE COMPANY
HAS RECEIVED AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED."

 

4.Conditions of Investor's
Obligations. The obligations of the Investor hereunder are subject to the fulfillment on or before the Closing of each of the
following conditions:

 

4.1Representations and Warranties.
The representations and warranties of the Company contained in Section 2 shall be true on and as of the Closing with the same effect
as though such representations and warranties had been made on and as of the date of such Closing.

 

4.2Performance. The
Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by it on or before the Closing.

 

4.3Board Actions. The
Company shall have delivered to the Investor resolutions duly adopted by the Company's Board of Directors and, to the extent required
by applicable law or by the Company's Articles of Incorporation, the Company's Shareholders, and certified by the Secretary of
the Company (i) approving and authorizing the Company's execution and delivery of this Agreement, the Notes and the Warrants, and
the Company's performance thereunder, and (ii) authorizing the reservation of a sufficient number of shares of the Company's Common
Stock to permit the conversion of the Notes and to permit the exercise of the Warrants.

 

5. Conditions
of the Company's Obligations. The obligations of the Company with respect to the Investor under this Agreement are subject
to the fulfillment on or before the Closing of each of the following conditions:

    	5

    	 

    

5.1Representations and
Warranties. The representations and warranties of the Investor contained in Section 3 and on the Investor's signature page
shall be true on and as of the Closing with the same effect as though such representations and warranties had been made on and
as of the Closing.

 

5.2Delivery of Principal.
The Investor shall have delivered the principal amount of the Investor's Investment as is prescribed in Section 1.1.

 

6.Post-Closing Covenant
of Company. During such times as any Note is outstanding, the Company shall provide the Investor with a weekly update of the
Company's actual and forecasted cash position and of any reasonably significant development related to the Company or its business.
Such weekly updates shall be transmitted to the Investor via facsimile or via e-mail, at a facsimile number or e-mail address provided
by the Investor, no later than noon pacific time each Monday during which such obligation remains in effect.

 

7.Reimbursement for Legal Fees.

 

The Company shall reimburse Investor
for the legal fees and administrative costs incurred by it in connection with the transactions contemplated by this Agreement in
an amount not to exceed Ten Thousand Dollars ($10,000).

 

8.Events of Default.

 

Upon the occurrence of any of the
following specified events (each an "Event of Default"), unless such Event of Default shall have been waived or cured
prior to the exercise of the remedies set forth below:

 

8.1 Payments.
Any default by the Company in the payment when due of any principal and unpaid accrued interest under any Note if such default
is not cured by the Company within ten (10) days after the holder of such Note has given the Company written notice of such default;

 

8.2Representations and Warranties.
Any representation or warranty made by the Company herein shall prove to have been incorrect in any material respect on or as of
the date made and remains unremedied for a period of thirty (30) days after any Investor provides the Company with written notice
of such breach;

 

8.3Post Closing Covenants.
The failure of Company to satisfy any of the post-closing covenants set forth in Section 6 hereof within the time-periods set forth
therein.

 

8.4Institution of Bankruptcy
Proceedings. The institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it
to institution of bankruptcy or insolvency proceedings against it or the filing by it of a petition or answer or consent seeking
reorganization or release under the federal Bankruptcy Act, or any other applicable federal or state law, or the consent by it
to the filing of any such petition or the appointment of a receiver, liquidator, assignee, trustee, or other similar official,
of the Company, or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors,
or the taking of corporate action by the Company in furtherance of any such action; or

    	6

    	 

    

 

8.5Continuation of Bankruptcy
Proceedings. If, within thirty (30) days after the commencement of an action against the Company (and service of process in
connection therewith on the Company) seeking any bankruptcy, insolvency, reorganization, liquidation, dissolution or similar relief
under any present or future statute, law or regulation, such action shall not have been resolved in favor of the Company or all
orders or proceedings thereunder affecting the operations or the business of the Company stayed, or if the stay of any such order
or proceeding shall thereafter be set aside, or if, within thirty (30) days after the appointment without the consent or acquiescence
of the Company of any trustee, receiver or liquidator of the Company or of all or any substantial part of the properties of the
Company, such appointment shall not have been vacated;

 

Then, and in any such event, and at any time thereafter,
if any events shall be continuing, the Investor shall have the option to declare the principal amount of the Notes, and all accrued
but unpaid interest thereon, to be immediately due and payable upon written notice to the Company.

 

9.Miscellaneous.

 

9.1Successors and Assigns.
Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon
the respective successors and assigns of the parties (including transferees of any securities). Nothing in this Agreement, express
or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

9.2Governing Law. This
Agreement shall be governed by and construed under the laws of the State of California, without giving effect to principles of
conflict of laws.

 

9.3 Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

9.4Titles and Subtitles.
The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement.

 

9.5Notices. Unless
otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively
given upon personal delivery to the party to be notified or four (4) days after deposit with the United States Post Office, by
registered or certified mail, postage prepaid and addressed to the party to be notified at the address indicated for such party
on the signature page hereof, or at such other address as such party may designate by advance written notice to the other parties.

    	7

    	 

    

 

9.6Finder's Fee.
Each party represents that it neither is nor will be obligated for any finders' fee or commission in connection with this transaction.

 

9.7Entire Agreement. This
Agreement and the other documents delivered pursuant hereto constitute the entire agreement among the parties and no party shall
be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically set
forth herein or therein.

 

9.8Amendment and Waiver.
Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in
a particular instance and either retroactively or prospectively), with the written consent of the Company and the Investor. This
provision shall not affect the amendment and waiver provisions of the Note. Any waiver or amendment effected in accordance with
this section shall be binding upon each holder of any Securities purchased under this Agreement at the time outstanding, each future
holder of all such Securities, and the Company.

 

9.9Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms.

 

9.10Survival. The representations,
warranties, covenants and agreements made herein shall survive the Closing for a period of 12 months.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	8

    	 

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first above written.

 

 

VG Life Sciences Inc.

 

 /s/ Haig Keledjian 

 haig
keledjian (Nov 26, 2013)

By: Haig Keledjian

Title: Chairman

 

 

 

MedBridge Venture Fund, LLC,

by its Managers:

 

Wild Harp Holdings, LLC

 

 

/s/ John P.Tynan

John P.Tynan (Nov 26, 2013) 

By: John P. Tynan, its Manager

 

 

DW Odell Company, LLC

 

 

/s/ David W Odell

By: David W. Odell, Manager

 

    	9

    	 

    

 

EXHIBIT A

 

CONVERTIBLE PROMISSORY NOTE

 

SEE ATTACHED.

 

 

 

 

 

 

    	10

    	 

    

 

 

EXHIBIT B

 

WARRANT TO PURCHASE COMMON STOCK

 

SEE ATTACHED.

 

 

 

 

 

    	11

    	 

    

 

EXHIBIT C

 

SERVICES TO BE PROVIDED BY MEDBRIDGE VENTURE
FUND, LLC

 

The following list outlines the services
to be provided by MedBridge Venture Fund, LLC to VG Life Sciences, Inc. for the period beginning July 13, 2013 and ending July
12, 2014 at a value of $50,000 per month:

 

Management Team including:

 

1.President & CEO (Mr. John Tynan)

 

2.Chief Operating Officer (Mr. Brennan de Raad)

 

3.Controller (Mr. Caleb Rhoads)

 

Grant Application
Coordinator

 

Administrative Assistant, Finance

 

Additional Public Relations Resources

 

The following list outlines the services to be provided by MedBridge
Venture Fund, LLC

to VG Life Sciences, Inc. for the period beginning July 13, 2014
and ending January 12,

2015 at a value of $22,500 per month:

 

Management Team including:

 

1.Chief Operating Officer

 

2.Controller

 

Grant Application Coordinator

 

Administrative Assistant, Finance

 

Additional Public Relations Resources

 

The total value of services to be provided by MedBridge Venture
Fund, LLC to VG Life Sciences, Inc. for the period beginning July 13, 2013 and ending January 12, 2015 is $735,000.

 

    	12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]